FDA approves first-ever drug to treat postpartum depression

(Photo by Larry Busacca/Getty Images)

The first-ever drug created specifically to combat postpartum depression was approved by the U.S. Food and Drug Administration (FDA) on Tuesday.

Zulresso, created by Sage Therapeutics, is an IV drug administered "as a continuous infusion" over the course of 60 hours, or two and a half days, the agency announced in a news release.

In a company-funded study of new mothers with moderate or severe postpartum depression, reportedly half the women given Zulresso had depression end within two and a half days — about double the rate of those in a comparison group given dummy treatments.

The New York Times reports the drug is estimated to cost $20,000 or more. 

Getting the "baby blues" after childbirth is common, according to the Mayo Clinic. After childbirth, "most" new mothers experience a range of symptoms, including mood swings, crying, trouble sleeping and irritability.

For more information, please visit FoxNews.com